Previous 10 | Next 10 |
Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug ...
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about ...
ATLANTA, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Milestone Pharmaceuticals Inc. (“Milestone Pharmaceuticals” or the “Company”) (NASDAQ: MIST) complied with federal securities laws. On December 26, 2023, the Company disc...
2023-12-26 13:19:25 ET Gainers: RayzeBio ( RYZB ) +101% . IMAC Holdings ( BACK ) +73% . Bit Brother Limited ( BETS ) +63% . Gracell Biotechnological ( GRCL ) +60% . Volcon ( VLCN ) +54% . Sight Sciences ( SGHT ) +45% ...
BOSTON, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about ...
2023-12-26 10:02:19 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...
2023-12-26 08:29:35 ET Losers: Alternus Clean Energy ( ALCE ) -42% . LeddarTech Holdings ( LDTC ) -27% . Milestone Pharmaceuticals ( MIST ) -28% receives refusal to file letter from U.S. FDA for new drug application for Etripamil in the treatment of...
2023-12-26 07:33:20 ET More on Milestone Pharmaceuticals Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals Historical earnings data for Milestone Pharmaceuticals Financial information for Milestone Pharmaceuticals For further details see: M...
MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-admin...
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Nov. 21, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its manageme...
News, Short Squeeze, Breakout and More Instantly...
Milestone Pharmaceuticals Inc. Company Name:
MIST Stock Symbol:
NYSE Market:
– NDA for etripamil in PSVT resubmitted in 1Q 2024 – Cash resources as of March 31, 2024 expected to fund operations into 2026 – Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing MONTREAL and ...
MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced upcoming data presentations on etripam...
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company...